Licensed Practical Nurse in Brooklyn, MD Accepting Medicare
3 Licensed Practical Nurse nurses found. Showing 1 - 3
 Shavene Ryals, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1002 E Patapsco Ave, Brooklyn, MD 21225 Phone: 410-355-2798 |
 Dr. Maxwell Mbah, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 731 Sunnyfield Ln, Brooklyn, MD 21225 Phone: 954-309-4017 Fax: 410-636-6029 |
Mrs. Denise Gabriella Jones, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 201 9th Ave, Brooklyn, MD 21225 Phone: 410-279-8293 |
News Archive
MGH-developed CTC-iChip with digital PCR assay improves detection of early-stage liver cancer
Use of an advanced form of the commonly used polymerase chain reaction (PCR) method to analyze circulating tumor cells (CTCs) may greatly increase the ability to diagnose early-stage cancer, increasing the likelihood of successful treatment.
Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel
In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus.
USPTO issues patent related to Seattle Genetics' ADC technology
Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.
Results from study of Rituxan in rheumatoid arthritis show promise
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
Novaquest closes $459 million private equity fund
NovaQuest Capital Management, L.L.C. is pleased to announce the final closing of NovaQuest Pharma Opportunities Fund III, L.P., a $459 million private equity fund focused on providing structured finance solutions to biopharmaceutical companies ("Fund III").
› Verified 2 days ago